Pathogen-reduced platelets for the prevention of bleeding

Cochrane Database of Systematic Reviews

Volumn 2017, Issue 7, 2017, Pages

  Estcourt, Lise J ^a   Malouf, Reem ^b   Hopewell, Sally ^b   Trivella, Marialena ^b   Doree, Carolyn ^a   Stanworth, Simon J ^c   Murphy, Michael F ^c  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c NIHR OXFORD BIOMEDICAL RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMOTOSALEN; RIBOFLAVIN; FUROCOUMARIN DERIVATIVE; PHOTOSENSITIZING AGENT;

BACTERIAL INFECTION; BLEEDING; HEART SURGERY; HEMATOLOGIC MALIGNANCY; HUMAN; INCIDENCE; INTERMETHOD COMPARISON; LIVER TRANSPLANTATION; MALIGNANT NEOPLASM; METHODOLOGY; MORTALITY; PARALLEL DESIGN; PATHOGEN REDUCED PLATELET; PATHOGEN REDUCTION SYSTEM; PHOTOCHEMISTRY; PRIORITY JOURNAL; QUALITY CONTROL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; SURGICAL PATIENT; SYSTEMATIC ERROR; SYSTEMATIC REVIEW; THROMBOCYTE; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT OUTCOME; ULTRAVIOLET A RADIATION; VIRUS INACTIVATION; ADULT; ANTISEPSIS; CHILD; DISEASE TRANSMISSION; HEMORRHAGE; META ANALYSIS; MICROBIOLOGY; PREVENTION AND CONTROL; PROCEDURES; ULTRAVIOLET RADIATION;

ADULT; ANTISEPSIS; BLOOD PLATELETS; CHILD; DISEASE TRANSMISSION, INFECTIOUS; FUROCOUMARINS; HEMORRHAGE; HUMANS; PHOTOSENSITIZING AGENTS; PLATELET TRANSFUSION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RIBOFLAVIN; THROMBOCYTOPENIA; ULTRAVIOLET RAYS;

EID: 85026448014     PISSN: None     EISSN: 1469493X     Source Type: Journal    
DOI: 10.1002/14651858.CD009072.pub3     Document Type: Review

References (143)

1. Agliastro RE, De Francisci G, Bonaccorso R, Spicola D, Ziino O, Arico M, et al. Clinical study in pediatric hemato-oncology patients: efficacy of pathogen inactivated buffy coat platelets versus aphaeresis platelets. Transfusion 2006;46(9s):117A. Abstract No. SP246. 2824137
2. Ambruso DR, Thurman G, Marschner S, Goodrich RP. Lack of antibody formation to platelet neoantigens after transfusion of riboflavin and ultraviolet light-treated platelet concentrates. Transfusion 2009;49(12):2631-6. [PUBMED: 19694996]2824141
3. Goodrich R, Roberts T, Follea G. Clinical evaluation of Mirasol PRT treated apheresis platelets in thrombocytopenic patients. Transfusion 2008;48(Suppl):20A. Abstract No. S49-020G. 2824142
4. Mirasol Clinical Evaluation Study Group. A randomized controlled clinical trial evaluating the performance and safety of platelets treated with MIRASOL pathogen reduction technology. Transfusion 2010;50(11):2362-75. [NCT00263809; PUBMED: 20492615]2824143
5. NCT00263809. Safety and performance of MIRASOL® PRT treated platelet transfusion products. clinicaltrials.gov/ct2/show/NCT00263809 first received 7 December 7 2005. 2824139
6. De Francisci G, Bonaccorso R, Bellavia D, D'Alia G, Fiandaca T, Giancana A, et al. Clinical trial on the use of pathogen inactivated platelets, with Helinx® technology, in cardio paediatric surgery and cirrhotic patients. Transfusion 2004;44(s1):17A. Abstract No. S48-0301. 2824145
7. Janetzko K, Cazenave JP, Kluter H, Kientz D, Michel M, Beris P, et al. Therapeutic efficacy and safety of photochemically treated apheresis platelets processed with an optimized integrated set. Transfusion 2005;45(9):1443-52. [PUBMED: 16131376]2824147
8. Johansson PI, Simonsen A, Ostrowski SR, Deberdt L, Marschner S, Goodrich R. TEG as a surrogate marker for the haemostatic function of PRT treated platelets in thrombocytopenic patients. Transfusion 2012;52(Suppl 3):67A. Abstract No. SP34. 2824149
9. Johansson PI, Simonsen AC, Brown PN, Ostrowski SR, Deberdt L, Van Hoydonck P, et al. A pilot study to assess the hemostatic function of pathogen-reduced platelets in patients with thrombocytopenia. Transfusion 13;53(9):2043-52. 2824150
10. NCT01368211. Mirasol-treated platelets - (Pathogen Reduction Extended Storage Study) (PRESS). clinicaltrials.gov/ct2/show/NCT01368211 first received 6 June 2011. 2824151
11. ISRCTN88278819. Clinical effectiveness and safety of pooled, random donor platelet concentrates, leukoreduced and stored up to seven days either in additive solution with and without pathogen reduction or plasma in haemato-oncological patients. www.isrctn.com/ISRCTN88278819 first received 8 February 2007. 6396598
12. Kerkhoffs JL, van Putten WL, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, et al. Clinical effectiveness of leucoreduced, pooled donor platelet concentrates, stored in plasma or additive solution with and without pathogen reduction. British Journal of Haematology 2010;150(2):209-17. [ISRCTN88278819; PUBMED: 20507310]2824154
13. Kerkhoffs JLH, Novotny VM, Te Boekhorst PA, Schipperus MR, Zwaginga JJ, van Pampus L, et al. Clinical effectiveness and safety of pooled, random donor platelet concentrates, leucoreduced and stored up to seven days in either plasma or additive solution with and without pathogen reduction in hemato-oncological patients. Transfusion 2009;49(s3):2A. Abstract No. P5-020A. 2824155
14. NTR861. Clinical effectiveness and safety of pooled, random donor platelet concentrates, leucoreduced and stored up to seven days either in additive solution with and without pathogen reduction or plasma in hemato-oncological patients. www.trialregister.nl/trialreg/admin/rctview.asp?TC=861 first received 11 January 2007. 2824153
15. Lozano M, Knutson F, Tardivel R, Cid J, Maymo RM, Lof H, et al. A multi-center study of therapeutic efficacy and safety of platelet components treated with amotosalen and UVA pathogen inactivation stored for 6 or 7 days prior to transfusion. British Journal of Haematology 2011;153(3):393-401. [PUBMED: 21418180]2824157
16. NCT00261924. Efficacy and safety study of platelets treated for pathogen inactivation and stored for up to seven days (TESSI). www.clinicaltrials.gov/ct2/show/NCT00261924 first received 5 December 2005. 2824158
17. Benjamin RJ, Goodnough LT, Lopez-Perez I, Strauss R, McCullough J, Slichter S, et al. Fresh (1-2 day-old) vs. aged (4-5 day-old) INTERCEPT platelets and conventional platelets provide comparable count increments. However fresh platelets result in superior hemostasis: results of the SPRINT trial. Transfusion 2003; Vol. 43, issue 9s:9A. Abstract No. S29-030E. 2824160
18. Conlan MGC, Vesole DH, Staudtmauer E, Goodnough LT, Coutre S, Howard FD, et al. Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation: results of the phase III SPRINT trial of Intercept platelets. Vox Sanguinis 2005; Vol. 89, issue Suppl 2:36-7. Abstract No. 5P-035. 2824161
19. Corash L, Eiden J, Lin S. Serious pulmonary adverse events and acute lung injury following repeated platelet transfusions. Transfusion 2008;48(s2):28A. Abstract No. S73-030F. 2824162
20. Corash L, Lin JS, Eiden J. Acute lung injury in patients receiving repeated platelet transfusions. Vox Sanguinis 2008; Vol. 95, issue Suppl 1:300-1. Abstract No. P-662. 2824163
21. Corash L, Lin JS, Sherman CD, Eiden J. Determination of acute lung injury following repeated platelet transfusions. Blood 2010; Vol. 117, issue 3:1014-20. [PUBMED: 20935256]2824164
22. 9/L is associated with increased pre-transfusion bleeding and increased platelet transfusions: results of the SPRINT study. Transfusion 2002;42(9s):17S. Abstract No. S62-030K. 2824165
23. McCullough J, Vesole D, Benjamin RJ, Slichter S, Pineda A, Snyder E, et al. Pathogen inactivated platelets using Helinx (TM) technology (INTERCEPT) are hemostatically effective in thrombocytopenic patients: the SPRINT trial. Blood 2001;98(11):450a. Abstract No. 1884. 2824166
24. McCullough J, Vesole DH, Benjamin RJ, Slichter SJ, Pineda A, Snyder E, et al. Therapeutic efficacy and safety of platelets treated with a photochemical process for pathogen inactivation: the SPRINT trial. Blood 2004;104(5):1534-41. [PUBMED: 15138160]2824167
25. Murphy S, Slichter S, McCullough J, Strauss R, Wood L, Lin J, et al. INTERCEPT platelets are hemostatically as effective as conventional platelets in the prophylaxis and treatment of bleeding: results of the SPRINT trial. Vox Sanguinis 2002;83(109):Abstract No. 329. 2824168
26. 11 results in comparable hemostasis and platelet and RBC transfusion requirements. Results of the SPRINT trial. Blood 2003;102(11 Pt 2):815a. Abstract No. 3018. 2824169
27. Murphy S, Snyder E, Cable R, Slichter SJ, Strauss RG, McCullough J, et al. Platelet dose consistency and its effect on the number of platelet transfusions for support of thrombocytopenia: an analysis of the SPRINT trial of platelets photochemically treated with amotosalen HCl and ultraviolet A light. Transfusion 2006;46(1):24-33. [PUBMED: 16398727]2824170
28. Pineda A, McCullough J, Benjamin RJ, Cable R, Strauss RG, Burgstaler E, et al. Pathogen inactivation of platelets with a photochemical treatment with amotosalen HCl and ultraviolet light: process used in the SPRINT trial. Transfusion 2006;46(4):562-71. [PUBMED: 16584432]2824171
29. Slichter SJ, Murphy S, Buchholz D, Lin J, Corash L, Conlan M. INTERCEPT platelets (plts) and conventional plts provide comparable hemostatic responses in thrombocytopenic patients: the SPRINT trial. Blood 2002; Vol. 100, issue 11 Pt 2:141b. Abstract No. 4048. 2824172
30. Snyder E, McCullough J, Slichter SJ, Strauss RG, Lopez-Plaza I, Lin JS, et al. Clinical safety of platelets photochemically treated with amotosalen HCl and ultraviolet A light for pathogen inactivation: the SPRINT trial. Transfusion 2005; Vol. 45, issue 12:1864-75. [PUBMED: 16371039]2824173
31. Strauss RG, Eastlund DT, Lopez-Plaza I, Lin JS, Conlan MG. INTERCEPT platelets provided effective hemostasis in thrombocytopenic children: Results of the SPRINT trial. Pediatric Research 2003; Vol. 53, issue 4:287A. Abstract No. 1635. 2824174
32. Strauss RG, Slichter S, Lopez-Plaza I, Goodnough LT, McCullough J, Lin J, et al. Intercept platelets exhibit immunologic refractoriness comparable to conventional platelets. Haematologica 2004;89(Suppl 1):Abstract No. 628. 2824175
33. Vesole D, Stadtmauer E, Goodnough LT, Coutre S, Howard F, Lin JS, et al. Source of donor stem cells impacts incidence of bleeding and platelet and RBC transfusion requirements during stem cell transplantation (SCT): results of the Phase III SPRINT trial of INTERCEPT pathogen inactivated platelets. Biology of Blood and Bone Marrow Transplantation 2004; Vol. 10, issue 2:233. 2824176
34. NCT01642563. Italian Platelet Technology Assessment Study (IPTAS). www.clinicaltrials.gov/ct2/show/NCT01642563 first received 13 July 2012. 2824179
35. Rebulla P, Grazzini G, Liumbruno GM, Aprili G, Formisano S, Girelli G, et al [The Italian Pathogen Technology Assessment Study (IPTAS) Research Group]. Pathogen inactivated platelets and prevention of immunological adverse reactions: the Italian Platelet Technology Assessment Study (IPTAS). Blood Transfusion 2009;7, Suppl 1:Abstract No. LE08. [DOI: 10.2450/2009.0013-09]2824178
36. Rebulla P, Vaglio S, Aprili G, Beccaria F, Coluzzi S, Girelli G, et al. Clinical efficacy and safety of platelets in additive solution treated with two commercial pathogen reduction technologies. Transfusion 2015;55(Suppl 3):3A. Abstract no. P2-030A. 6396599
37. Simonsen AC, Johansson PI, Conlan MG, Jacquet M, Lin JS, Junge K, et al. Transfusion of 7-day-old amotosalen photochemically treated buffy-coat platelets to patients with thrombocytopenia: a pilot study. Transfusion 2006;46(3):424-33. [PUBMED: 16533286]2824181
38. Slichter SJ, Corash L, Davis K, Metzel P, Lin L, Buchholz DH. Hemostatic function of photo-chemically treated (PCT) platelets (PLTS) in thrombocytopenic patients. Vox Sanguinis 2000;79(Suppl 1):Abstract No. O102. 2824183
39. Slichter SJ, Raife TJ, Davis K, Rheinschmidt M, Buchholz DH, Corash L, et al. Platelets photochemically treated with amotosalen HCl and ultraviolet A light correct bleeding times in patients with thrombocytopenia. Transfusion 2006;46(5):731-40. [PUBMED: 16686840]2824184
40. Cazenave JP, Davis K, Corash L. Design of clinical trials to evaluate the efficacy of platelet transfusion: the euroSPRITE trial for components treated with Helinx technology. Seminars in Hematology 2001;38(4 Suppl 11):46-54. [PUBMED: 11727285]2824186
41. Cazenave JP, van Rhenen D, Gulliksson H, Pamphilon D, Ljungman P, Davis K, et al. INTERCEPT buffy coat platelets (IPC) are effective during multiple episodes of thrombocytopenia: the EUROSPRITE trial. Transfusion Clinique et Biologique 2001;8(Suppl 1):132s. Abstract No. P267. 2824187
42. Corash L, Cazenave JP, van Rhenen D, Gullikksson H, Pamphilon D, Ljungman P, et al. Platelets treated with HELINX™ technology (HPC) are effective for multiple cycles of transfusion support of thrombocytopenia: the euroSPRITE trial. Transfusion 2001;41(Suppl):38S. Abstract No. S133-040K. 2824188
43. Corash L, Klueter H, Rhenen D, Gulliksson H, Pamphilon D, Cazenave JP, et al. Intercept platelet concentrates (IPC) are effective and safe for support of multiple cycles of thrombocytopenia: the EUROSPRITE Phase III Trial. Haematologica 2001;86(Suppl 1):Abstract No. 667. 2824189
44. Kluter H, Chapuis B, Cazenave JP, Hastka J, Beris P, Dufour P, et al. Apheresis platelets treated with the INTERCEPT Blood System for pathogen inactivation provide platelet count increments and hemostasis comparable to conventional platelets. Vox Sanguinis 2002;83(110a):Abstract No. 331. 2824190
45. Ljungman P, van Rhenen D, Pamphilon D, Metzel P, Marblie S, Lin L, et al. Results of the EUROSPRITE phase III trial: INTERCEPT buffy coat platelet concentrates (IPC) provide effective hemostasis for thrombocytopenic (TCP) patients (pts). Transfusion Clinique et Biologique 2001;8(Suppl 1):100s. Abstract No. P147. 2824191
46. Pamphilon D, Buchholz DH, Cazenave JP, Conlan M, Corash L, Davis K, et al. The EUROSPRITE phase III trial of INTERCEPT buffy coat platelet concentrates (IPC) demonstrates IPC are safe when transfused to thrombocytopenic (TCP) patients (PTS). Transfusion Clinique et Biologique 2001;8(Suppl 1):100-1s. Abstract No. P148. 2824192
47. Sintnicolaas K, Flament J, Corash L, van Rhenen D. Clinical refractoriness and HLA alloimmunisation are infrequent after multiple exposures to INTERCEPT-TM platelets. Transfusion Clinique et Biologique 2001;8(Suppl 1):100s, 133s. Abstract No. P146 & P269. 2824193
48. van Rhenen D, Gulliksson H, Cazenave JP, Pamphilon D, Ljungman P, Kluter H, et al. Transfusion of pooled buffy coat platelet components prepared with photochemical pathogen inactivation treatment: the euroSPRITE trial. Blood 2003;101(6):2426-33. [PUBMED: 12456508]2824194
49. van Rhenen D, Gulliksson H, Pamphilon D, Cazenave JP, Ljungman P, Davis K, et al. S-59 (Helinx™) photochemically treated platelets (plt) are safe and effective for support of thrombocytopenia: results of the Eurosprite phase 3 trial. Blood 2000;96(11):819a. Abstract No. 3539. 2824195
50. Andreu G, Norol F, Schooneman F, Coffe C, Pouthier F, Soulier J, et al. Prevention of HLA alloimmunization using UV-B irradiated platelet concentrates (PC): results of a prospective randomized clinical trial. Transfusion 1993;33(9s):73S. Abstract No. S283. 2824197
51. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2004;44(s1):16A-7A. Abstract No. S47-0301. 2824199
52. AuBuchon JP, Herschel L, Roger J, Taylor H, Whitley P, Li J, et al. Efficacy of apheresis platelets treated with riboflavin and ultraviolet light for pathogen reduction. Transfusion 2005;45(8):1335-41. [PUBMED: 16078923]2824200
53. Ayupova F. Clinical application of transfused platelet concentrates treated with Intercepttm blood system technology-experience from ufa center. 33rd International Congress of the International Society of Blood Transfusion, in Conjunction with the 33rd Congress of the KSBT and the 2014 Congress of the Korean Hematology Societies Seoul, South Korea 2014;107:130-1. 2824202
54. Berger K, Bauer M, Schopohl D, Henschler R, Ostermann H. Model calculations to quantify clinical and economic effects of pathogen inactivation in platelet concentrates. Onkologie 2013;39(1-2):53-9. 2824204
55. Blundell EL, Pamphilon DH, Fraser ID, Menitove JE, Greenwalt TJ, Snyder EL, et al. A prospective, randomized study of the use of platelet concentrates irradiated with ultraviolet-B light in patients with hematologic malignancy. Transfusion 1996;36(4):296-302. [PUBMED: 8623127]2824206
56. Cid J, Escolar G, Lozano M. Therapeutic efficacy of platelet components treated with amotosalen and ultraviolet A pathogen inactivation method: results of a meta-analysis of randomized controlled trials. Vox Sanguinis 2012;103:322-30. [DOI: 10.1111/j.1423-0410.2012.01614.x]6396601
57. Cook RJ, Heddle NM. Clinical trials evaluating pathogen-reduced platelet products: methodologic issues and recommendations. Transfusion 2013;53(8):1843-55. 2824208
58. Corash LM, Paton V, Wages D, Rheinschmidt M, Porter S, Cimino G, et al. S-59 clearance and kinetics after transfusion of platelets treated with Helinx™ technology. Transfusion 2000;40(Suppl):37S. Abstract No. S137-040I. 2824210
59. Corash L. Frequency of respiratory adverse events (AE) reported during active hemovigilance after transfusion of INTERCEPTTM Platelet Components (PC). AABB Annual Meeting and CTTXPO 2012; 2012 Oct 6-9; Boston, MA. 2012. 2824212
60. Drawz SM, Marschner S, Yanez M, Garcia De Coca A, Feys HB, Deeren D, et al. Observational study of corrected count increments after transfusion of platelets treated with riboflavin pathogen reduction technology in additive solutions. Transfusion 2015;55(7):1745-51. 2824214
61. Dumont LJ, Dumont DF, Unger ZM, Siegel A, Szczepiorkowski ZM, Corson JS, et al. A randomized controlled trial comparing autologous radiolabeled in vivo platelet recoveries and survivals of 7-day stored PRP and buffy coat platelets from the same donors. Transfusion 2010;50(s2):1A-2A. Abstract P3-020A. 2824216
62. Infanti L, Stebler C, Job S, Ruesch M, Gratwohl A, Irsch J, et al. Pathogen-inactivation of platelet components with the INTERCEPT Blood SystemTM: a cohort study. Transfusion and Apheresis Science 2011;45(2):175-81. 2824218
63. MacLennan S, Harding K, Llewelyn C, Choo L, Bakrania L, Massey E, et al. A randomized noninferiority crossover trial of corrected count increments and bleeding in thrombocytopenic hematology patients receiving 2- to 5- versus 6- or 7-day-stored platelets. Transfusion 2015;55(8):1856-65. 2824220
64. MacLennan S, Harding K, Llewelyn C, Choo L, Bakrania L, Massey E, et al. Comparison of platelets stored for 2-5 vs 6-7 days in preventing and treating haemorrhage in thrombocytopenic patients - a randomised controlled trial. Vox Sanguinis 2013;105:42. 2824221
65. NCT00742001. Feasibility study of Mirasol-treated whole blood red cell recovery and survival. clinicaltrials.gov/ct2/show/NCT00742001 first received 25 August 2008. 2824223
66. NCT01615146. Outpatient Platelet Transfusions in Myelodysplastic Syndromes and Leukemia: The OPTIMAL Pilot. clinicaltrials.gov/ct2/show/NCT01615146 first received 6 June 2012. 2824225
67. NCT02330081. Survival and recovery of radio-labeled platelets derived from Mirasol-treated whole blood (Medic). clinicaltrials.gov/ct2/show/NCT02330081 first received 30 December 2014. 2824227
68. NCT02653443. A randomized, multi-center, open-label, paired controlled, crossover in vivo study to assess the recovery and lifespan of radiolabeled autologous INTERCEPT treated apheresis platelet components suspended in nominal 35% plasma and 65% InterSol stored for 6 or 7 days. clinicaltrials.gov/ct2/show/NCT02653443 first received 2 December 2015. 6396603
69. Rummler S, Weinigel C, Weise C, Barz D. Efficacy and safety of pathogen reduced plasma in plasma therapy in Germany. AABB Annual Meeting and CTTXPO 2013; 2013 Oct 12-15; Denver, CO. 2013. 2824229
70. Sigle JP, Infanti L, Studt JD, Martinez M, Stern M, Gratwohl A, et al. Comparison of transfusion efficacy of amotosalen-based pathogen-reduced platelet components and gamma-irradiated platelet components. Transfusion 2013;53(81):1788-97. 2824231
71. TRAP Study Group. Leukocyte reduction and ultraviolet B irradiation of platelets to prevent alloimmunization and refractoriness to platelet transfusions. The Trial to Reduce Alloimmunization to Platelets Study Group. New England Journal of Medicine 1997;337(26):1861-9. [PUBMED: 9417523]2824233
72. Vamvakas EC. Meta-analysis of the studies of bleeding complications of platelet pathogen-reduced with the Intercept system. Vox Sanguinis 2012;102(4):302-16. [PUBMED: 21957897]2824235
73. Phase III, randomised, double-blind, multi-centre clinical trial on clinical efficacy and safety of platelet concentrates treated with the THERAFLEX UV Platelets procedure in comparison to conventional platelet components (Capture). Ongoing study June 2016.
74. NCT02783313. Pathogen Reduction Evaluation & Predictive Analytical Rating Score (PREPAReS). www.clinicaltrials.gov/ct2/show/NCT02783313 first received 11 April 11 2016. [NTR2106]2824239
75. NTR2106. The PREPAReS Study: Pathogen Reduction Evaluation & Predictive Analytical Rating Score. www.trialregister.nl/trialreg/admin/rctview.asp?TC=2106 first received 13 November 2009. 2824237
76. Ypma PF, van der Meer PF, Heddle NM, van Hilten JA, Stijnen T, Middleburg RA, et al. A study protocol for a randomised controlled trial evaluating clinical effects of platelet transfusion products: the Pathogen Reduction Evaluation and Predictive Analytical Rating Score (PREPAReS) trial. BMJ Open 2016;6:e010156. 6396605
77. NCT01789762. Evaluation of the efficacy of platelets treated with pathogen inactivation process (EFFIPAP). www.clinicaltrials.gov/ct2/show/NCT01789762 first received 8 February 2013. 6396607
78. Benjamin RJ, Dy B, Perez J, Eder AF, Wagne SJ. Bacterial culture of apheresis platelets: a mathematical model of the residual rate of contamination based on unconfirmed positive results. International Society of Blood Transfusion 2014;106:23-30.
79. Blajchman MA, Vamvakas EC. The continuing risk of transfusion-transmitted infections. New England Journal of Medicine 2006;355:1303-5.
80. Bolton-Maggs P (Ed), Poles D, et al. on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2014 Annual SHOT Report. SHOT, 2015.
81. Bolton-Maggs P (Ed), Poles P, et al. on behalf of the Serious Hazards of Transfusion (SHOT) Steering Group. The 2015 Annual SHOT Report. SHOT, 2016.
82. Cazenave JP, Isola H, Waller C, Mendel I, Kientz D, Laforêt M, et al. Use of additive solutions and pathogen inactivation treatment of platelet components in a regional blood center: impact on patient outcomes and component utilization during a 3-year period. Transfusion 2011;51:622-9.
83. Charlton A, Wallis J, Robertson J, Watson D, Iqbal A, Tinegate H. Where did platelets go in 2012? A survey of platelet transfusion practice in the north of England. Transfusion Medicine 2014;24:213-8.
84. Ciaravino V, McCullough T, Cimino G, Sullivan T. Preclinical safety profile of plasma prepared using the INTERCEPT Blood System. Vox Sanguinis 2003;85(3):171-82.
85. Veritas Health Innovation. Covidence systematic review software. Melbourne, Australia: Veritas Health Innovation, 2016.
86. Deeks JJ, Higgins JPT, Altman DG (editors). Chapter 9: Analysing data and undertaking meta-analyses. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
87. European Medicines Agency. ICH Topic E2A Clinical safety data management: definitions and standards for expedited reporting. www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf (accessed prior to 20 July 2017).
88. Estcourt L, Stanworth S, Doree C, Hopewell S, Murphy MF, Tinmouth A, et al. Prophylactic platelet transfusion for prevention of bleeding in patients with haematological disorders after chemotherapy and stem cell transplantation. Cochrane Database of Systematic Reviews 2012, Issue 5. [DOI: 10.1002/14651858.CD004269.pub3]
89. Estcourt LJ, Heddle N, Kaufman R, McCullough J, Murphy MF, Slichter S, et al. The challenges of measuring bleeding outcomes in clinical trials of platelet transfusions. Transfusion 2013;53(7):1531-43.
90. Faddy HM, Fryk JJ, Watterson D, Young PR, Modhiran N, Muller DA, et al. Riboflavin and ultraviolet light: impact on dengue virus infectivity. Vox Sanguinis 2016;111:235-41.
91. Fedele PL, Polizzotto MN, Grigoriadis G, Waters N, Comande M, Borosak M, et al. Profiling clinical platelet and plasma use to inform blood supply and contingency planning: PUPPY, the prospective utilization of platelets and plasma study. Transfusion 2016;56:2455-65.
92. Fillet AM, Desmarets M, Assari S, Quaranta JF, François A, Pugin A, et al. Blood products use in France: a nationwide cross-sectional survey. Transfusion 2016;56(12):3033-41.
93. Goodnough LT, Shander A, Brecher ME. Transfusion medicine: looking to the future. Lancet 2003;361:161-9.
94. Goodrich RP, Edrich RA, Li J, Seghatchian J. The Mirasol PRT system for pathogen reduction of platelets and plasma: an overview of current status and future trends. Transfusion and Apheresis Science 2006;35(1):5-17.
95. Grass JA, Hei DJ, Metchette K, Cimino GD, Wiesehahn GD, Corash L, et al. Inactivation of leukocytes in platelet concentrates by photochemical treatment with psoralen plus UVA. Blood 1998;91:2180-8.
96. Hardwick CC, Herivel TR, Hernandez SC, Ruane PH, Goodrich RP. Separation, identification and quantification of riboflavin and its photoproducts in blood products using high-performance liquid chromatography with fluorescence detection: a method to support pathogen reduction technology. Photochemistry and Photobiology 2004;80(3):609-15.
97. Hauser L, Roque-Afonso AM, Beylouné A, Simonet M, Deau Fischer B, Nicolas Burin des Roziers N, et al. Hepatitis E transmission by transfusion of Intercept blood system-treated plasma. Blood 2014;123(5):796-7.
98. Higgins JPT, Deeks JJ (editors). Chapter 7: Selecting studies and collecting data. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
99. Higgins JPT, Altman DG, Sterne JAC (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
100. Higgins JPT, Deeks JJ, Altman DG (editors). Chapter 16: Special topics in statistics. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
101. Hong H, Xiao W, Lazarus HM, Good CE, Robert W, Maitta RW, et al. Detection of septic transfusion reactions to platelet transfusions by active and passive surveillance. Blood 2015;127(4):1-30.
102. Jacobs MR, Good CE, La HM. Relationship between bacterial load, species virulence, and transfusion reaction with transfusion of bacterially contaminated platelets. Clinical Infectious Diseases 2008;46:1214-20.
103. Janetzko K, Klinger M, Mayaudon V, Lin L, Eichler H, Klüter H. Storage characteristics of split double-dose platelet concentrates derived from apheresis and treated with amotosalen hydrochloride and UVA light for pathogen inactivation. Transfusion Medicine and Hemotherapy 2002;29(4):193-8.
104. Jones A, Birchall J, Roberts P, Davies L, Webb M, Cooke SJ, et al. A survey of where and why platelets are used in hospitals in the South West region of England. Transfusion Medicine 2013;23:PO34.
105. Knutson F, Osselaer J, Pierelli L, Lozano M, Cid J, Tardivel R, et al. A prospective, active haemovigilance study with combined cohort analysis of 19175 transfusions of platelet components prepared with amotosalen-UVA photochemical treatment. International Journal of Transfusion Medicine 2015;109:343-52.
106. Kumar VK, Lockerbi O, Keil SD, Ruane PH, Platz MS, Martin CB, et al. Riboflavin and UV-light based pathogen reduction: extent and consequence of DNA damage at the molecular level. Photochemistry and Photobiology 2004;80:15-21.
107. Kwon SY, Kim IS, Bae JE, Kang JW, Cho YJ, Cho NS, et al. Pathogen inactivation efficacy of Mirasol PRT System and Intercept Blood System for non-leucoreduced platelet-rich plasma-derived platelets suspended in plasma. Vox Sanguinis 2014;107:254-60.
108. Lefebvre C, Manheimer E, Glanville J. Chapter 6: Searching for studies. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
109. Lin L, Alfonso R, Behrman B. Photochemical treatment of platelet concentrates with a novel psoralen and UVA to enhance the safety of platelet transfusion. Infusion Therapy Transfusion Medicine 1998;25(1):39-48.
110. Lin L, Dikeman R, Molini B, Lukehart SA, Lane R, Dupuis K, et al. Photochemical treatment of platelet concentrates with amotosalen and long-wavelength ultraviolet light inactivates a broad spectrum of pathogenic bacteria. Transfusion 2004;44(10):1496-504.
111. Lin L, Hanson CV, Alter HJ, Jauvin V, Bernard KA, Murthy KK, et al. Inactivation of viruses in platelet concentrates by photochemical treatment with amotosalen and long-wavelength ultraviolet light. Transfusion 2005;45(4):580-90.
112. McCullough J. Pathogen inactivation: a new paradigm for preventing transfusion-transmitted infections. American Journal of Clinical Pathology 2007;28:945-55.
113. Moog R, Fröhlich A, Mayaudon V, Lin L. In vitro evaluation of COM.TEC apheresis platelet concentrates using a preparation set and pathogen inactivation over a storage period of five days. Journal of Clinical Apheresis 2004;19(4):185-91.
114. Osselaer JC, Messe N, Hervig T, Bueno J, Espinosa A, Accorsi P, et al. A prospective observational cohort safety study of 5106 platelet transfusions with components prepared with photochemical pathogen inactivation treatment. Transfusion 2009;48:1061-71.
115. Osselaer JC, Doyen C, Defoin L, Debry C, Goffaux M, Messe N, et al. Universal adoption of pathogen inactivation of platelet components: impact on platelet and red blood cell component use. Transfusion 2009;49:1412-22.
116. Owada T, Kaneko M, Matsumoto C, Sobata R, Igarashi M, Suzuki K, et al. Establishment of culture systems for Genotypes 3 and 4 hepatitis E virus (HEV) obtained from human blood and application of HEV inactivation using a pathogen reduction technology system. Transfusion 2014;54:2820-7.
117. Parmar MK, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Statistics in Medicine 1998;17(24):2815-34.
118. Pearce S, Rowe GP, Field SP. Screening of platelets for bacterial contamination at the Welsh Blood Service. Transfusion Medicine 2011;21:25-32.
119. Pelletier JPR, Transue S, Snyder SL. Pathogen inactivation techniques. Best Practice & Research Clinical Haematology 2006;19(1):205-42.
120. Perez-Pujol S, Tonda R, Lozano M, Fuste B, Lopez-Vilchez I, Galan AM, et al. Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005;45(6):911-9.
121. 2) for pathogen-reduction. Vox Sanguinis 2009;97(1):26-33.
122. Reddy HL, Dayan AD, Cavagnaro J, Gad S, Li J, Goodrich RP. Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfusion Medicine Reviews 2008;22:133-5.
123. Reesink HW, Panzer S, McQuilten ZK, Wood EM, Marks DC, Wendel S, et al. Pathogen inactivation of platelet concentrates. Vox Sanguinis 2010;99:85-95.
124. The Nordic Cochrane Centre, The Cochrane Collaboration. Review Manager (RevMan). Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014.
125. Ruane PH, Edrich R, Gampp D, Keil SD, Leonard RL, Goodrich RP, et al. Photochemical inactivation of selected viruses and bacteria in platelet concentrates using riboflavin and light. Transfusion 2004;44:877-85.
126. Schünemann HJ, Oxman AD, Vist GE, Higgins JPT, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
127. Slichter SJ, Kaufman RM, Assmann SF, McCullough J, Triulzi DJ, Strauss RG, et al. Dose of prophylactic platelet transfusions and prevention of hemorrhage. New England Journal of Medicine 2010;362(7):600-13.
128. Snyder E, Raife T, Lin L, Cimino G, Metzel P, Rheinschmidt M, et al. Recovery and life span of 111indium-radiolabeled platelets treated with pathogen inactivation with amotosalen HCl (S-59) and ultraviolet A light. Transfusion 2004;44(12):1732-40.
129. Sterne JAC, Egger M, Moher D (editors). Chapter 10: Addressing reporting biases. In: Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from handbook.cochrane.org.
130. Tice RR, Gatehouse D, Kirkland D, Speit G. The pathogen reduction treatment of platelets with S-59 HCl (Amotosalen) plus ultraviolet A light: genotoxicity profile and hazard assessment. Mutation Research 2007;630(1-2):50-68.
131. Tierney JF, Stewart LA, Ghersi D, Burdett S, Sydes MR. Practical methods for incorporating summary time-to-event data into meta-analysis. Trials 2007; Vol. 8, issue 16. [DOI: 10.1186/1745-6215-8-16]
132. Triulzi DJ, Assmann SF, Strauss RG, Ness PM, Hess JR, Kaufman RM, et al. The impact of platelet transfusion characteristics on post-transfusion platelet increments and clinical bleeding in patients with hypo-proliferative thrombocytopenia. Blood 2012;119(23):5553-62.
133. US Food, Drug Administration. What is a serious adverse event?. www.accessdata.fda.gov/scripts/medwatch/medwatch-online.htm (accessed 4 May 2012).
134. Vamvakas EC. Meta-analysis of the randomized controlled trials of the hemostatic efficacy and capacity of pathogen-reduced platelets. Transfusion 2011;51(5):1058-71.
135. Van Rhenen DJ, Vermeij J, Mayaudon V, Hind C, Lin L, Corash L. Functional characteristics of S-59 photochemically treated platelet concentrates derived from buffy coats. Vox Sanguinis 2000;79(4):206-14.
136. World Bank. World Bank country and lending groups: current classification by income. datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups (accessed September 2016).
137. Webert KE, Arnold DM, Lui Y, Carruthers J, Arnold E, Heddle NM. A new tool to assess bleeding severity in patients with chemotherapy-induced thrombocytopenia. Transfusion 2012;52(11):2466-74.
138. Whitaker BI, Hinkins S. The 2011 National Blood Collection and Utilization Survey Report. www.hhs.gov/ash/bloodsafety/nbcus/ (accessed prior to 20 July 2017).
139. World Health Organization. Blood transfusion safety: haemovigilance. www.who.int/bloodsafety/haemovigilance/en/ (accessed prior to 20 July 2017).
140. Zou S, Stramer SL, Dodd RY. Donor testing and risk: current prevalence, incidence, and residual risk of transfusion-transmissible agents in US allogeneic donations. Transfuion Medicine Reviews 2012;26(2):119-28.
141. Łetowska M, Przybylska Z, Piotrowski D, Lachert E, Rosiek A, Rzymkiewicz L, et al. Hemovigilance survey of pathogen-reduced blood components in the Warsaw Region in the 2009 to 2013 period. Transfusion 2016;56:S39-44.
142. Butler C, Doree C, Estcourt L, Stanworth S, Brunskill SJ, Hopewell S, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database of Systematic Reviews 2011, Issue 4. [DOI: 10.1002/14651858.CD009072]
143. Butler C, Doree C, Estcourt LJ, Trivella M, Hopewell S, Brunskill SJ, et al. Pathogen-reduced platelets for the prevention of bleeding. Cochrane Database of Systematic Reviews 2013, Issue 3. [DOI: 10.1002/14651858.CD009072.pub2]